Alkermes’ alixorexton is the first orexin 2 receptor agonist to show efficacy in phase 2 trials involving patients with both main narcolepsy subtypes.
Novo’s double departures: As GLP-1 luminary retires, an obesity leader goes to Boehringer Ingelheim
→ A decorated GLP-1 pioneer is retiring at Novo Nordisk. Channeling Elvis Presley with a microphone emoji for good measure, Lotte Bjerre Knudsen said on

